The effects of sPLA2 inhibitors (PIP-18 and LY315920) and MAPK inhibitors (SB202190, PD98059, SP600125) on IL-1β-induced MMP and sPLA2 production by RA SF are shown in Figure 4b. The gene discussed is IL1B; the disease is rheumatoid arthritis.